Concepedia

Mirella Lazarov

ML

Statistics

Publications

11

Citations

1.2K

H-Index

11

Active since

1999

Affiliations

Stanford University(Current)

Gilead Sciences (United States)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Sarah Cannon

Mirella Lazarov is an author at Stanford University specializing in medicine, pharmacology, and molecular oncology.

ORCID

Publications per year

1999–2020

11

Publications

11

NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia

Maya Dajee, Mirella Lazarov, Jennifer Zhang et al. · Nature · 2003 · 538 citations

, , +12

CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis

Mirella Lazarov, Yoshiaki Kubo, Ti Cai et al. · Nature Medicine · 2002 · 202 citations

, , +12

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha et al. · Clinical Cancer Research · 2014 · 133 citations · Full text

, , +17

Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis

Simon Travis, Lee Min Yap, Chris Hawkey et al. · Inflammatory Bowel Diseases · 2005 · 122 citations · Full text

, , +16

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

Jeff P. Sharman, Steven Coutré, Richard R. Furman et al. · Blood · 2014 · 82 citations

, , +14

1–5 of 11